Interferon-α adjuvant therapy decreases the recurrence of early clear cell renal cell carcinoma and improves the prognosis of Chinese patients
Year: 2017
Type: article
Abstract: // Hang Yin 1, * , Cheng-Gong Liao 1, * , Jian-Guo Huang 1 , Yong-Qiang Wang 1 , Zheng Li 1 , Lu-Lu Fan 1 , Men-Long Qian 1 , Nao Wan 1 and Ning Lu 1 1 Department of Oncology, General Hospital of Xinjiang Military Command, Urumqi 830000, P.R. China * These authors contributed equally to this work Correspondence to: Ning Lu, email: [email protected] Keywords: clear cell renal cell carcinoma, interferon-α, immunotherapy, recurrence Received: November 16, 2016 Accepted: June 02, 2017 Published: June 19, 2017 ABSTRACT The survival time of patients with early clear cell renal cell carcinoma (ccRCC) is fairly long, but 20% to 30% of patients with localized tumors experience relapse, and the effect of IFN-α on survival has not been well studied in patients with early ccRCC. In this study, 208 patients with early ccRCC were treated with surgery, and 54 of the patients received IFN-α as adjuvant therapy. The remaining 115 patients were treated with surgery but not with IFN-α therapy. The primary endpoint was the recurrence rate, 20.37% (11/54) and 33.04% (38/115) in the IFN-α and surgery-only group, respectively. The secondary endpoint was progression-free survival (PFS), which was 123.70 (95% CI: 107.18–140.22) months for the IFN-α group, and 95.80 (95% CI: 82.18–109.42) months for the non-IFN-α group; this difference was significant ( P < 0.05). The main side effects were pyrexia (61.11%), muscle pain (24.07%), malaise (9.26%), anorexia (5.56%), hepatic dysfunction (3.70%) and renal dysfunction (1.85%). Moreover, a multivariate regression identified older age, higher BMI index and smoking as significant and independent predictors of decreased PFS ( P < 0.05). Overall, IFN-α therapy significantly improved PFS in Chinese patients with early ccRCC and was an independent prognostic factor ( P < 0.05). In conclusion, our study showed that adjuvant IFN-α therapy decreased the recurrence rate and prolonged PFS in patients with ccRCC. Thus, this treatment may help clinicians to select a better treatment modality and better predict survival in these patients.
Source: Oncotarget
Authors: Hang Yin, Cheng-Gong Liao, Jian-Guo Huang, Yong-Qiang Wang, Zheng Li, Lu-Lu Fan, Men-Long Qian, Nao Wan, Ning Lu
Institution: Urumqi General Hospital of PLA
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W2712222515